Loading...
XSHG
603363
Market cap1.14bUSD
Jul 10, Last price  
2.94CNY
1D
3.52%
1Q
-25.38%
IPO
-49.64%
Name

Fujian Aonong Biological Technology Group Incorporation Ltd

Chart & Performance

D1W1MN
XSHG:603363 chart
P/E
103.44
P/S
0.95
EPS
0.03
Div Yield, %
Shrs. gr., 5y
32.66%
Rev. gr., 5y
-5.95%
Revenues
8.47b
-3.29%
2,953,809,5214,184,442,7044,012,709,1174,978,470,5974,902,660,0975,761,891,9475,788,080,06611,517,165,75718,038,160,16021,613,039,52119,457,641,1308,762,672,7698,474,746,757
Net income
78m
-86.60%
24,991,36442,745,07433,776,94291,375,510108,118,87430,125,65729,155,735572,989,301-1,519,871,690-1,038,366,498-3,650,822,221579,345,02877,621,595
CFO
153m
P
137,262,6040129,237,958128,952,36826,775,90027,261,152394,159,196406,022,923524,291,286663,636,691984,006,832-116,781,234152,943,412
Dividend
Jun 08, 20210.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fujian Aonong Biological Technology Group Incorporation Limited operates across diverse sectors, including animal feed production, swine farming, agricultural raw material trading, digital agricultural platforms, and bio-pharmaceuticals, serving both domestic Chinese and international markets. Its activities encompass the research, development, manufacturing, and distribution of various animal feed products, including specialized formulations for pigs, poultry, aquatic species, and ruminants. Furthermore, the company manages pig breeding facilities and is involved in the processing and slaughtering of swine. Aonong Biological Technology also supplies a range of veterinary products, such as vaccines, medicinal preparations, micro-ecological agents, powdered supplements, premixes, liquid oral treatments, feed additives, and disinfectants. Additionally, it develops and maintains an intelligent platform designed to support breeding services. Established in Xiamen, China, the company commenced operations in 2011.
IPO date
Sep 26, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT